1152
HETEROCYCLES, Vol. 76, No. 2, 2008
NMR (CDCl3, 125 MHz): δ 209.6, 133.7, 61.2, 48.8, 43.9, 36.7, 26.1, 23.5; HRMS (ESI-TOF) (m/z): [M +
H]+ calcd for C9H14N3O, 180.1131; found, 180.1129.
(3i): IR (υ[cm-1]) = 3122, 2926, 2862, 1699, 1447, 1220, 1112, 1072, 1027, 791, 757, 730; 1H NMR (CDCl3,
500 MHz): δ 7.67 (s, 1H), 7.56 (s, 1H), 4.83 (tt, J = 10.8, 3.3, 1H), 3.28 (dd, J = 14.5, 11.0, 1H), 2.92 (ddd,
J = 14.8, 2.5, 2.0, 1H), 2.66−2.61 (m, 1H), 2.53 (ddd, J = 16.0, 11.3, 4.0, 1H), 2.30−2.26 (m, 1H), 2.18 (tdd,
J = 14.0, 11.3, 2.8, 1H), 2.07−1.96 (m, 2H), 1.80−1.72 (m, 1H), 1.64−1.56 (m, 1H); 13C NMR (CDCl3, 125
MHz): δ 209.0, 133.7, 121.5, 57.6, 49.8, 43.9, 37.7, 26.4, 23.5; HRMS (ESI-TOF) (m/z): [M + H]+ calcd for
C9H14N3O, 180.1131; found, 180.1128.
3-Methyl-4-(2H-1,2,3-triazol-2-yl)pentan-2-one (4j)
Prepared using method B, 3-methylpent-3-en-2-one (2j) (491 mg, 5 mmol), NH-1,2,3-triazole (304 μL,
5.25 mmol), 65 °C. Purified by column chromatography (50% EtOAc/hexanes to 100% EtOAc) to afford 4j
as a colorless oil (0.45 g, 54%) and 3j (0.15 g, 18%) as the minor product:
(4j) (isolated as a 1:1 mixture of diastereomers): IR (υ[cm-1]) = 3123, 2986, 2940, 1712, 1452, 1420, 1339,
1152, 1081, 961, 818; Diastereomer A: 1H NMR (CDCl3, 500 MHz): δ 7.60 (s, 1H), 5.01 (dq, J = 8.5, 6.8,
1H), 3.35 (dq, J = 8.5, 7.5, 1H), 2.08 (s, 3H), 1.55 (d, J = 6.5, 3H), 1.18 (d, J = 7.0, 3H); 13C NMR (CDCl3,
1
125 MHz): δ 209.6, 133.8, 61.8, 51.3, 28.8, 17.5, 13.2; Diastereomer B: H NMR (CDCl3, 500 MHz): δ
7.56 (s, 1H), 4.96 (dq, J = 9.3, 6.8, 1H), 3.20 (dq, J = 9.3, 7.3, 1H), 2.22 (s, 3H), 1.53 (d, J = 6.5, 3H), 0.81
(d, J = 7.0, 3H); 13C NMR (CDCl3, 125 MHz): δ 209.5, 133.7, 62.5, 53.0, 29.7, 19.2, 14.0; HRMS
(ESI-TOF) (m/z): [M + H]+ calcd for C8H14N3O, 168.1131; found, 168.1126.
(3j) (isolated as a 1:1 mixture of diastereomers): IR (υ[cm-1]) = 3128, 2983, 2941, 1709, 1453, 1360, 1224,
1115, 1077, 953, 792; Diastereomer A: 1H NMR (CDCl3, 500 MHz): δ 7.69 (d, J = 1.0, 1H), 7.55 (d, J = 1.0,
1H), 4.88-4.82 (m, 1H), 3.29 (dq, J = 8.8, 7.3, 1H), 2.04 (s, 3H), 1.58 (d, J = 7.0, 3H), 1.21 (d, J = 7.0, 3H);
13C NMR (CDCl3, 125 MHz): δ 209.8, 133.3, 123.1, 57.8, 51.7, 29.2, 18.3, 13.8; Diastereomer B: 1H NMR
(CDCl3, 500 MHz): δ 7.63 (d, J = 1.0, 1H), 7.53 (d, J = 1.0, 1H), 4.88-4.82 (m, 1H), 3.18 (dq, J = 8.8, 7.3,
1H), 2.22 (s, 3H), 1.57 (d, J = 6.5, 3H), 0.88 (d, J = 7.0, 3H); 13C NMR (CDCl3, 125 MHz): δ 209.5, 133.1,
123.5, 58.1, 52.7, 29.7, 19.7, 14.0; HRMS (ESI-TOF) (m/z): [M + H]+ calcd for C8H14N3O, 168.1131;
found, 168.1128.
ACKNOWLEDGEMENTS
The authors thank Drs. S. M. Pitram and J. C. Tripp and Ms. J. Raushel for assisting in the preparation of
this manuscript. Financial support for this work was provided by the National Institute of General Medical
Sciences, National Institute of Health (GM28384), the Skaggs Institute for Chemical Biology, and the W.
M. Keck Foundation (K.B.S.). We also thank the Skaggs Foundation for a graduate student fellowship